Coronary microvascular dysfunction is highly prevalent in HFpEF and correlates with systemic endothelial dysfunction and heart failure severity, highlighting it as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
CMD assessment in HFpEF remains hypothesis-generating; prospective trials needed before any therapeutic targeting.
Shah et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: